Hypertrophic Cardiomyopathy
Research activity is centered on hypertrophic cardiomyopathy, with attention to both obstructive and non-obstructive forms. The clinical focus includes symptom burden, functional limitation, and disease-related impairment in people living with this cardiac muscle disorder.
- Symptomatic hypertrophic cardiomyopathy
- Obstructive cardiomyopathy
- Non-obstructive hypertrophic cardiomyopathy
The sponsor’s interest in this area reflects a focus on cardiology and the management of structural heart disease.
Cardiometabolic Therapy
The funded research includes evaluation of sotagliflozin in hypertrophic cardiomyopathy, linking the sponsor’s work to cardiometabolic treatment and symptom control in a population with significant functional limitations.
- Sotagliflozin
- Symptom improvement
- Functional capacity
This area aligns with therapeutic interest in agents that may address both cardiac symptoms and broader metabolic pathways.
Patient-Reported Outcomes
Clinical interest extends to changes in symptoms and functional limitations, emphasizing the lived experience of patients with hypertrophic cardiomyopathy and the impact of treatment on daily activity.
- Symptom burden
- Functional limitation
- Quality of life
These outcomes place importance on how cardiac disease affects physical performance and patient experience.
International Cardiology Research
The sponsor supports a multicountry research footprint across North America, Europe, and other active regions, with collaboration across numerous research sites in studies of cardiac disease.
- Multinational trial activity
- Collaborating research sites
- Active recruitment
This distribution supports clinical investigation in specialist cardiovascular care settings.
